Menu
Search
|

Menu

Close
X

AveXis Inc AVXS.OQ (NASDAQ Stock Exchange Global Select Market)

119.16 USD
+2.46 (+2.11%)
As of 12:33 AM IST
chart
Previous Close 116.70
Open 117.87
Volume 58,005
3m Avg Volume 176,271
Today’s High 121.05
Today’s Low 117.87
52 Week High 127.15
52 Week Low 53.94
Shares Outstanding (mil) 31.93
Market Capitalization (mil) 3,310.99
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 18 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-4.662
FY16
-3.713
FY15
-3.066
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
7.50
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-46.56
14.43
Return on Equity (TTM)
vs sector
-46.61
16.13

EXECUTIVE LEADERSHIP

Daniel Welch
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Sean Nolan
President, Chief Executive Officer, Director, Since 2015
Salary: $448,462.00
Bonus: --
Phillip Donenberg
Principal Financial Officer, Senior Vice President, Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Lori Smith
Chief Human Resource Officer, Senior Vice President, Since 2017
Salary: --
Bonus: --
Michael Johannesen
Senior Vice President, Chief Compliance Officer, General Counsel, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2275 Half Day Rd Ste 160
BANNOCKBURN   IL   60015-1221

Phone: +1972.7257797

AveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either have experienced a deletion of their SMN1 genes, which prevents them from producing adequate levels of functional SMN protein, or carry a mutation in their SMN1 gene. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels.

SPONSORED STORIES